Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Wockhardt
ClinicalTrials.gov Identifier:
NCT00752180
First received: September 12, 2008
Last updated: December 26, 2012
Last verified: December 2012
  Purpose

The aim of this trial is to demonstrate bioequivalence of Wosulin R to Actrapid with regard to its total and to its maximum serum insulin concentrations.


Condition Intervention Phase
Diabetes
Biological: Wosulin R
Biological: Actrapid
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: A Single Dose,Single Centre,Double Blind,Crossover Study Comparing the Pharmacokinetic Profiles of Wockhardt's Insulin Human Injection, Soluble (Recombinant DNA Origin) for Injection and Actrapid in Type 1 Diabetics

Resource links provided by NLM:


Further study details as provided by Wockhardt:

Primary Outcome Measures:
  • Mean AUCins.0-12h and Cins.max [ Time Frame: Visit 2 and 3 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • PK endpoints: AUC0-4h, AUC0-6h, AUC6-12h,tmax, t½ and elimination rate constant.PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR6-12h, AUCGIR0-12h, GIRmax and tGIRmax .Safety endpoints: AEs, hematology, biochemistry, urinalyses, physical exam [ Time Frame: Visit 2, 3 and 4 ] [ Designated as safety issue: Yes ]

Enrollment: 28
Study Start Date: August 2008
Study Completion Date: April 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Wosulin R
Wosulin R,Regular insulin for injection(Recombinant Human Insulin)(600 nmol/ml, 100IU/ml)in vials 10.0 ml given subcutaneously.
Biological: Wosulin R
Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
Active Comparator: Actrapid
Actrapid, Regular insulin for injection (Recombinant Human Insulin) (600nmol/ml,100IU/ml)in vials 10.0 ml given subcutaneously.
Biological: Actrapid
Total dose per subject will be 0.3 IU/kg given Subcutaneously.
Other Name: Actrapid

Detailed Description:

The purpose of this study is to test for bioequivalence based on the pharmacokinetic parameters Cmax and AUC0-12h between two recombinant soluble human insulin preparations. The study also compares the other pharmacokinetic parameters and pharmacodynamic profiles as well as assesses safety and local tolerability of the two insulin preparations in type 1 diabetics.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects with type 1 diabetes mellitus
  • Age between 18 and 45 years (both inclusive)
  • Insulin treatment for at least 12 months before the screening visit
  • Daily basal insulin requirement between 0.2 and 0.6 IU/kg/day (both inclusive) and current total daily insulin dose less than 1.2 IU/kg/day.
  • Body Mass Index (BMI) between 18.0 and 35.0 kg/m2
  • HbA1c less than or equal to 10.0%
  • Fasting C-peptide < 0.4 nmol/L
  • Non-smoker, no nicotine consumption for at least one year.
  • Subjects considered generally healthy, except for the underlying diabetes mellitus and related morbidity (such as well controlled hypertension and dyslipidemia)
  • Signed and dated informed consent obtained before any trial-related activities

Exclusion Criteria:

  • Previous participation in this trial or other clinical trials within 30 days of dosing or 5 half-lives of any investigational drug, whichever is longer. If half life of the investigational drug is unknown, previous participation in other clinical trials within 3 months of dosing.
  • Pregnant, breast-feeding or intention of becoming pregnant or not using adequate contraceptive measures (defined as intrauterine device that has been in place for at least 3 months, double barrier contraception, sterilization or abstinence, or oral contraceptive pill, which should have been taken without difficulty for at least 3 months, or an approved hormonal implant).
  • Clinically significant abnormal hematology or biochemistry screening tests, as judged by the Investigator. In particular, subjects with elevated liver enzymes (AST or ALT > 2 times the upper limit of normal) or impaired renal function will not be allowed to enter the trial.
  • Any serious systemic infectious disease during the four weeks prior to first dose of test drug,
  • History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial drug to the subject. In particular, subjects with significant cardiovascular disease, anemia or hemoglobinopathy will not be allowed to enter the trial.
  • Cardiac problems defined as: decompensated heart failure (NYHA class III and IV) at any time and/or angina pectoris and/or myocardial infarction within the last 12 months.
  • Uncontrolled hypertension
  • Subjects who have at screening, after 5 minutes rest, a supine blood pressure outside the range of 90-140 mmHg systolic or 50-90 mmHg diastolic, or pulse rate outside the range 40 to 90 beats per minute, or who are requiring more than two anti-hypertensive medications.
  • Severe neuropathy (in particular autonomic neuropathy), retinopathy or maculopathy
  • Clinically significant abnormal ECG at screening
  • Recurrent major hypoglycemia or hypoglycemic unawareness as judged by the investigator or hospitalization for diabetic ketoacidosis during the 6 months preceding the screening visit.
  • History of alcohol or drug abuse in the past five years and/or any positive test for drugs of abuse at screening.
  • Positive test for hepatitis B or C or HIV
  • Any systemic treatment with drugs known to interfere with glucose metabolism such as systemic corticoids, non-selective beta-blockers, thyroid hormone and monoamine oxidase inhibitors within 3 months prior to the first dosing visit.
  • Use of drugs which may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilization or recovery from hypoglycemia
  • Blood donation of more than 500 mL within the last 12 weeks
  • History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction
  • Known or suspected allergy to trial products or related products
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00752180

Locations
United States, California
Profil Institute for Clinical Research
Chula Vista, California, United States, 91911
Sponsors and Collaborators
Wockhardt
Investigators
Study Director: Till Schroer Profil Institute for Clinical Research, Inc.
  More Information

No publications provided

Responsible Party: Wockhardt
ClinicalTrials.gov Identifier: NCT00752180     History of Changes
Other Study ID Numbers: WosulinR/PK-PD/type1/EMEA/2008
Study First Received: September 12, 2008
Last Updated: December 26, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Wockhardt:
pharmacokinetics
pharmacodynamics
type 1 diabetics
recombinant human insulin

Additional relevant MeSH terms:
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014